Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Nivalis Thera Cmn ST (NVLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 35,392
  • Shares Outstanding, K 15,660
  • Annual Sales, $ 0 K
  • Annual Income, $ -31,460 K
  • 36-Month Beta 0.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.68

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.05 +2.44%
on 04/24/17
3.04 -30.92%
on 04/03/17
-0.74 (-26.06%)
since 03/24/17
3-Month
2.05 +2.44%
on 04/24/17
3.63 -42.15%
on 03/14/17
-0.07 (-3.23%)
since 01/24/17
52-Week
2.00 +5.00%
on 12/12/16
9.35 -77.54%
on 09/20/16
-2.63 (-55.60%)
since 04/22/16

Most Recent Stories

More News
Nivalis' (NVLS) Shares Down After Merger Deal with Alpine

The announcement of Nivalis Therapeutics, Inc.'s (NVLS) merger agreement with a privately-held biotechnology company, Alpine Immune Sciences, Inc. failed to excite investors.

CORT : 9.20 (+0.99%)
GRFS : 20.26 (+1.55%)
INFI : 1.96 (+2.08%)
NVLS : 2.10 (-7.08%)
Nivalis Therapeutics, Inc. and Alpine Immune Sciences, Inc. Agree to Combine

--- Combined Company Well Capitalized with $90 Million in Funding to Advance Discovery and Development -

NVLS : 2.10 (-7.08%)
KITE : 82.25 (+3.46%)
How These Biotech Stocks are Faring? -- Corbus Pharma, Advaxis, Vanda Pharma, and Nivalis Therapeutics

On Monday, March 06, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Monday's trading session in bearish territories....

ADXS : 8.27 (+1.85%)
CRBP : 6.40 (-1.54%)
NVLS : 2.10 (-7.08%)
VNDA : 14.75 (+2.08%)
Nivalis Therapeutics Announces Results from Phase 2 Clinical Trial of Cavosonstat Added to Ivacaftor for Treatment of Cystic Fibrosis

Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a pharmaceutical company historically focused on developing innovative solutions for people with cystic fibrosis (CF), today announced topline results from the...

NVLS : 2.10 (-7.08%)
Bristol-Myers to Not Seek Accelerated Approval for Opdivo+Yervoy

Bristol-Myers (BMY) won't seek an accelerated approval in the U.S. for the combination of its two immuno-oncology treatments Opdivo plus Yervoy for the first-line lung cancer.

ANIK : 44.47 (+1.58%)
MRK : 62.14 (+0.40%)
NVLS : 2.10 (-7.08%)
BMY : 53.55 (+0.13%)
BioLineRx (BLRX) Starts Cancer Study on BL-8040+Keytruda

BioLineRx (BLRX) announced the initiation of a second phase IIa study on BL-8040 in combination with Keytruda for the treatment of pancreatic cancer.

MRK : 62.14 (+0.40%)
NVLS : 2.10 (-7.08%)
RHHBY : 32.0100 (+1.30%)
BLRX : 0.85 (-3.41%)
Dr. Vikram Singh Joins MKS Instruments to Lead the Plasma & Power Business Units

MKS Instruments, Inc. (NASDAQ:MKSI), a global provider of technologies that enable advanced processes and improve productivity, announced today that Dr. Vikram Singh has joined the company as Vice President...

MKSI : 73.15 (+3.03%)
NVLS : 2.10 (-7.08%)
Nivalis Therapeutics Announces Review of Strategic Alternatives

Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on developing innovative solutions for people with cystic fibrosis (CF), today announced that its Board of Directors...

NVLS : 2.10 (-7.08%)
New Strong Buy Stocks for December 30th

New Strong Buy Stocks for December 30th

AMTD : 39.13 (+3.16%)
CATB : 1.50 (+3.45%)
ALRM : 32.53 (+1.62%)
NVLS : 2.10 (-7.08%)
STAY : 17.19 (-0.29%)
Zoetis (ZTS) Thrives on Product Portfolio, Risks Persist

On Dec 29, 2016, we issued an updated research report on Zoetis Inc. (ZTS).

SCMP : 9.65 (+2.12%)
AKBA : 9.31 (+2.31%)
ZTS : 54.99 (+1.48%)
NVLS : 2.10 (-7.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Nivalis Therapeutics, Inc. is a pharmaceutical company. The company is engaged in discovery, development and commercialization of molecule therapeutics for cystic fibrosis. Nivalis Therapeutics, Inc. is headquartered in Boulder, Colorado.

See More

Support & Resistance

2nd Resistance Point 2.50
1st Resistance Point 2.38
Last Price 2.10
1st Support Level 2.20
2nd Support Level 2.14

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.